Trump’s Deal with Eli Lilly & Novo Nordisk. After Trump’s Deal, How Much Will Weight-Loss Drugs Cost?
Eli Lilly and Novo Nordisk have reached unprecedented agreements with President Donald Trump that will drastically lower the cost of their well-known weight-loss medications.
Depending on the dosage and a patient’s insurance coverage, the monthly cost of popular injections and impending pills might be between $50 and $350 (about ₹4,000 to ₹29,000), according to these agreements.
Many patients cannot afford the current GLP-1 medications, such as Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound (for obesity), which are listed at more than $1,000 per month.
An Important Move by the Trump Administration
Under the “Most Favored Nation” policy, the Trump administration negotiated deals with both businesses on Thursday to increase access to these medications. In addition to providing patients with respite, these agreements will enable businesses to offer their goods directly to customers.
Under the new agreements, patients may pay the following amounts for weight-loss medications:
Medicare (Senior Government Health Insurance)
Medicare previously only paid for GLP-1 medications for diabetes and a few other illnesses, such Wegovy’s ability to lower cardiovascular risk.
But under the new agreements, Medicare will begin to pay for these medications for the treatment of obesity in the middle of 2026. Millions of senior persons are anticipated to gain from this, and commercial insurers are encouraged to do the same.
For these medications, some qualified Medicare patients will only need to pay a $50 monthly co-pay.
Nonetheless, the Trump administration has established particular eligibility categories for Medicare recipients who are eligible to obtain these medications. There are three categories for eligibility:
First group: Individuals with prediabetes or established cardiovascular disease who had a BMI more than 27.
Individuals with a BMI over 30 who additionally have heart failure, kidney disease, or uncontrolled hypertension make up the second category.
Those with severe obesity, or a BMI of more than 35, make up the third category.
Novo Nordisk and Eli Lilly have voluntarily agreed to lower the government’s monthly purchase price of these medications to $245. Medicare will be able to give patients with obesity and significant metabolic or cardiovascular risks the same price because to the savings from these pricing reductions.
Trump’s Deal with Eli Lilly & Novo Nordisk
Direct Sales to Customers
Additionally, consumers will receive even greater savings when purchasing the medications directly thanks to this partnership.
Next year, the government’s new direct-to-consumer portal, TrumpRx, will go live, enabling patients to pay with cash for prescription drugs.
Wegovy, Zepbound, and other GLP-1 injections will start at $350 per month on TrumpRx and progressively decrease to $250 over the course of the following two years.
The new Eli Lilly and Novo Nordisk medications will be offered on TrumpRx, Medicare, and Medicaid, with a beginning monthly cost of $145.
Regulators will also give these new medications expedited approval.
Additionally, Eli Lilly has announced a $50 discount on LillyDirect, its own platform. The lowest dose of Zepbound will now cost $299 per month, while higher doses would cost $449.
The lowest dosage of Eli Lilly’s medication will cost $149 per month once it is approved.
Medicaid is a state-based health program.
Up until now, Medicaid coverage of GLP-1 medications for obesity has been uneven; some states have covered them, while others have not.
The government pricing of $245 per month (for all non-starting doses) will now be extended to all 50 state Medicaid programs for all covered uses by Novo Nordisk and Eli Lilly.
However, not all states will automatically take part in this pricing arrangement; each state must choose to do so.
For information about coverage, patients are encouraged to contact their state government.
In Synopsis
Millions of Americans struggling with diabetes and obesity now have access to reasonably priced weight-loss medicines thanks to these new agreements from the Trump administration.
This is a new chapter for pharmaceutical behemoths like Eli Lilly and Novo Nordisk, one that strikes a balance between industry innovation and healthcare accessibility. Trump’s Deal with Eli Lilly & Novo Nordisk: Weight-Loss Drug Prices Drop to $50.
